Carol J Whelan

Author PubWeight™ 12.91^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.	JACC Cardiovasc Imaging	2013	3.53
2	Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.	Blood	2012	1.80
3	Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study.	Circ Cardiovasc Imaging	2012	1.25
4	Senile systemic amyloidosis: clinical features at presentation and outcome.	J Am Heart Assoc	2013	1.20
5	Systemic amyloidosis in England: an epidemiological study.	Br J Haematol	2013	1.08
6	The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients.	Am Heart J	2012	1.03
7	Cardiac transthyretin amyloidosis.	Heart	2012	0.93
8	Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.	Eur Heart J	2011	0.87
9	Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.	Br J Haematol	2014	0.82
10	Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.	Cardiovasc Ther	2014	0.80
11	CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy.	JACC Cardiovasc Imaging	2017	0.75